Key facts
- Notable investors include Grid Exponential.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Arakion
- ·The full record, as it builds
Funding rounds
No funding rounds for Arakion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arakion
Developer of an AI-powered biotech platform intended to offer AI-Powered Bioinsecticides from Arachnid Venom. The company's platform combines artificial intelligence and experimental biology to design novel peptide-based bioinsecticides, targeting high-value agricultural pests with safer and more effective chemicals, enabling users to tackle critical agricultural pests with novel modes of action, with AI-based protein design, experimental validation, and recombinant expression.
- Sector
- Healthcare
- HQ
- Mexico City, Mexico
- Founded
- 2025
- Employees
- 4
- Website
- arakion.bio/
- Ownership
- Privately Held (backing)
Arakion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arakion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arakion in its N-PORT filings yet. We sweep new filings monthly.